Dr. Simon on the Evaluation of Datopotamab Deruxtecan in TROP-2–Expressing Solid Tumors

Video

George Simon, MD, FACP, FCCP, discusses the evaluation of datopotamab deruxtecan in TROP-2–overexpressing solid tumors.

George Simon, MD, FACP, FCCP, chair, Department of Medical Oncology, Advent Health, department chair, Medical Oncology, Moffit Cancer Center, discusses the evaluation of datopotamab deruxtecan (DS-1062) in TROP-2–overexpressing solid tumors.

The phase 1 TROPION-PanTumor01 trial (NCT03401385) evaluated the safety and tolerability of the TROP-2–targeting antibody-drug conjugate (ADC), datopotamab deruxtecan.

The goal of the study was to understand how TROP-2–overexpressing solid tumors reacted to datopotamab deruxtecan, Simon adds. 

The trial served as a preliminary step before ADC is evaluated in combination with other therapies and against the current standard of care, Simon continues. The phase 1 study will inform a more detailed portfolio of studies that will come down the line, Simon concludes.

Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive(R).

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD